Mesenchymal stem cell therapy ameliorates metabolic dysfunction and restores fertility in a PCOS mouse model through interleukin-10

Abstract Background Polycystic ovary syndrome (PCOS) is the most common endocrine and metabolic disorder in reproductive-age women. Excessive inflammation elevated androgen production from ovarian theca cells are key features of PCOS. Human bone marrow mesenchymal stem (BM-hMSC) their secreted factors (secretome) exhibit robust anti-inflammatory capabilities various biological systems. We evaluated therapeutic efficacy BM-hMSC its secretome both vitro vivo PCOS models. Methods For experiment, we treated conditioned media to androgen-producing H293R analyzed gene expression. were implanted into letrozole (LTZ)-induced mouse model. effect or model mice was assessed by monitoring cell proliferation (immunohistochemistry), steroidogenic expression (quantitative real-time polymerase chain reaction [qRT-PCR] Western blot, animal tissue assay (H&E staining), fertility pup delivery. Results significantly downregulate expression, curb inflammation, restore animals. The cytokine interleukin-10 (IL-10) played a role mediating effects our demonstrated that treatment improved reproductive markers able fertility. Conclusion Our study demonstrates for first time intra-ovarian injection treat PCOS-related phenotypes, including dysfunction. This approach may represent novel option women with results suggest can reverse PCOS-induced through IL-10 secretion. might be treatment.